Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

• Marco Montillo,
• Alessandra Tedeschi,
• Gianluca Gaidano,
• Marta Coscia,
• Valeria Belsito Petrizzi,
• Ester Orlandi,
• Nicola Cascavilla,
• Paolo Ghia,
• Marina Motta,
• Andrea Gallamini,
• Anna Maria Frustaci,
• Davide Rossi,
• Lorenzo De Paoli,
• Michele Nichelatti,
• Enrica Morra,
• Massimo Massaia

Affiliations

Marco Montillo

Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milano

Alessandra Tedeschi

Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milano

Gianluca Gaidano

Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara

Marta Coscia

Hematology Division, University of Torino and Center for Experimental Research and Medical Studies, Torino

Valeria Belsito Petrizzi

Oncology and Hematology Unit, General Hospital, Nocera Inferiore, Pavia

Ester Orlandi

Department of Oncology-Hematology, Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia

Nicola Cascavilla

Hematology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Milan

Paolo Ghia

Lymphoma Unit, Department of Onco-Hematology, San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan

Marina Motta

Division of Hematology, Spedali Civili, Brescia

Andrea Gallamini

Hematology Division, Cuneo Hospital, Milano, Italy

Anna Maria Frustaci

Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milano

Davide Rossi

Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara

Lorenzo De Paoli

Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara

Michele Nichelatti

Service of Biostatistics, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milano, Italy

Enrica Morra

Department of Oncology/Haematology, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milano

Massimo Massaia

Hematology Division, University of Torino and Center for Experimental Research and Medical Studies, Torino